GLEEVEC (imatinib mesylate) Patient Assistance Program
Don’t let the high cost of brand specialty oral oncology therapy disrupt your treatment. We help eligible patients access Gleevec (imatinib mesylate) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Gleevec (imatinib mesylate) is FDA-approved for Philadelphia chromosome-positive chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), KIT-positive gastrointestinal stromal tumors (GIST), aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans (DFSP), and several other rarer indications.
- Without assistance, brand Gleevec costs commonly run approximately $9,000–$11,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Gleevec for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- Generic imatinib is now widely available at substantially lower cost — often $150–$400/month with a coupon. Generic imatinib is the same molecule and is FDA-bioequivalent to Gleevec. For most patients, generic imatinib is the more affordable path.
What Is Gleevec Prescription Assistance Program?
The Gleevec Prescription Assistance Program is a manufacturer-sponsored initiative that provides Gleevec at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for CML, GIST, and other approved indications in patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, brand Gleevec costs roughly $9,000–$11,000/month. Generic imatinib is dramatically cheaper. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$10,500 | Save ~$10,430/mo |
| CVS Pharmacy (brand) | ~$11,000 | Save ~$10,930/mo |
| Walmart (brand) | ~$9,500 | Save ~$9,430/mo |
| Costco (brand) | ~$9,200 | Save ~$9,130/mo |
Generic imatinib | ~$200 | Already low |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Gleevec Prescription Program?
The Patient Assistance Program is free to apply for and provides Gleevec at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic imatinib widely available at low cost, generic is usually the most affordable path for most patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Gleevec:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $9,000–$11,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Gleevec assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Gleevec Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Gleevec :
Gleevec (imatinib mesylate) is a once-daily oral tyrosine kinase inhibitor (TKI) used to treat several cancers driven by abnormal tyrosine kinase signaling. It was the first targeted cancer therapy approved (2001) and transformed CML from a typically fatal disease into one with near-normal life expectancy for many patients.
How Gleevec Works:
Chronic Myeloid Leukemia (CML) is driven by the BCR-ABL fusion gene, a chromosomal translocation known as the Philadelphia chromosome that creates a constitutively active tyrosine kinase causing uncontrolled cell growth. Aberrant tyrosine kinase signaling similarly drives KIT-positive Gastrointestinal Stromal Tumors (GIST) and PDGFR-driven tumors. Imatinib works by binding directly to the ATP-binding site of these specific tyrosine kinases, blocking their activity and halting the growth signals fueling the cancer. This targeted approach results in dramatic molecular responses in CML and significant tumor shrinkage in GIST, proving that specific molecular targeting can successfully transform cancer outcomes.
Form and use:
Gleevec is taken orally once every day and must be consumed alongside food and a large glass of water. Standard adult dosages are condition-dependent, requiring 400 mg daily for chronic phase CML, 600 to 800 mg daily for accelerated phase or blast crisis CML, and 400 to 800 mg daily for GIST. Pediatric dosing is customized based on the patient’s weight rather than standard flat amounts. Because managing these conditions requires continuous suppression, treatment is typically a long-term commitment that often lasts for years or even lifelong for CML patients.
Generic availability:
Generic imatinib is widely available across the United States at a substantially lower cost than the brand-name medication Gleevec. Beyond imatinib, there are several other tyrosine kinase inhibitors (TKIs) authorized for CML, including generic dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Second-generation options like dasatinib, nilotinib, and bosutinib are capable of achieving faster molecular responses than imatinib. Consequently, a physician’s choice between these available options may lean toward these second-generation TKIs for selected high-risk patients.
Warnings:
Gleevec carries notable warnings for edema and severe fluid retention, which can manifest dangerously as pulmonary edema, pleural or pericardial effusions, and ascites. It is associated with cytopenias, hepatotoxicity, and gastrointestinal bleeding or perforation, alongside a risk of tumor lysis syndrome right at the start of therapy. Patients with existing cardiac risk factors face a risk of cardiomyopathy and congestive heart failure, while thyroidectomized patients taking levothyroxine risk developing hypothyroidism. Finally, the medication carries warnings for dermatologic toxicity, embryo-fetal toxicity, and significant drug interactions with both CYP3A4 inhibitors and inducers.
FAQ (Frequently Asked Questions)
How Much Does Gleevec Cost Without Insurance?
Brand Gleevec costs approximately $9,000–$11,000 per 30-day supply. Generic imatinib is dramatically cheaper, often $150–$400/month with a coupon. Through AffordMyPrescriptions, qualifying patients receive Gleevec at no medication cost — our $69.95 monthly fee covers full advocacy and program management. Most patients find generic imatinib is the cheaper path.
Is Generic Imatinib The Same As Brand Gleevec?
Yes. The FDA requires generics to be bioequivalent to brand. Generic imatinib has the same active ingredient at the same dose as Gleevec. Most oncologists are comfortable using generic imatinib. Studies have shown comparable molecular response rates with generic imatinib in CML.
How Long Will I Be On Gleevec?
For CML, treatment is typically long-term — often years to lifelong — to maintain molecular remission. Some patients with sustained deep molecular response for many years may be candidates for treatment-free remission attempts under careful monitoring, but stopping should only be done in clinical trials or with very close monitoring under expert oncology guidance. For GIST, treatment continues as long as benefit is seen.
How Will My Doctor Monitor My Response?
For CML: BCR-ABL transcript levels (by RT-PCR) are checked at baseline, every 3 months until you achieve major molecular response (MMR, BCR-ABL ≤0.1% IS), then every 3–6 months thereafter. Complete blood counts and chemistries are checked regularly. For GIST: imaging (CT) every 3–6 months
What Should I Do About Side Effects?
Common side effects include nausea, diarrhea, muscle cramps, periorbital edema, fluid retention, fatigue, rash, low blood counts, and elevated liver enzymes. Most are manageable. Tell your oncologist about significant fluid retention (sudden weight gain, leg swelling, shortness of breath), severe muscle cramps or weakness, signs of infection, unusual bleeding/bruising, severe GI symptoms, or yellowing of skin/eyes.
Are There Drug Interactions I Should Know About?
Yes. Imatinib is metabolized by CYP3A. Strong CYP3A inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice) raise imatinib levels. Strong CYP3A inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John’s wort) lower imatinib levels and may reduce effectiveness. Imatinib also affects metabolism of warfarin, statins, and other medications. Tell every prescriber and pharmacist about all medications and supplements.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic imatinib (much cheaper), or to another CML TKI with its own PAP, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Leukemia & Lymphoma Society, GIST Support International, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Gleevec, our team may be able to help you access assistance programs — or guide you to generic imatinib if it fits your situation. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.